Kymera Therapeutics, Inc. (KYMR)
72.59
-5.22
(-6.71%)
USD |
NASDAQ |
Jan 02, 12:14
Kymera Therapeutics EPS Diluted (Quarterly): -0.9413 for Sept. 30, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Gilead Sciences, Inc. | 2.434 |
| Regeneron Pharmaceuticals, Inc. | 13.62 |
| Cytokinetics, Inc. | -2.552 |
| TG Therapeutics, Inc. | 2.428 |
| Protagonist Therapeutics, Inc. | -0.6169 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -82.18M |
| Revenue (Quarterly) | 2.764M |
| Total Expenses (Quarterly) | 84.94M |
| Enterprise Value | 5.177B |
| Gross Profit Margin (Quarterly) | 22.25% |
| Profit Margin (Quarterly) | -2.97K% |
| Earnings Yield | -4.95% |
| Normalized Earnings Yield | -4.912 |